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Abstract
Background: The purpose of this study was to evaluate collagen deposition, mRNA collagen synthesis and TGF-
beta expression in the lung tissue in an experimental model of scleroderma after collagen V-induced nasal
tolerance.
Methods: Female New Zealand rabbits (N = 12) were immunized with 1 mg/ml of collagen V in Freund’s adjuvant
(IM). After 150 days, six immunized animals were tolerated by nasal administration of collagen V (25 μg/day) (IM-
TOL) daily for 60 days. The collagen content was determined by morphometry, and mRNA expressions of types I, III
and V collagen were determined by Real-time PCR. The TGF-beta expression was evaluated by immunostaining
and quantified by point counting methods. To statistic analysis ANOVA with Bonferroni test were employed for
multiple comparison when appropriate and the level of significance was determined to be p < 0.05.
Results: IM-TOL, when compared to IM, showed significant reduction in total collagen content around the vessels
(0.371 ± 0.118 vs. 0.874 ± 0.282, p < 0.001), bronchioles (0.294 ± 0.139 vs. 0.646 ± 0.172, p < 0.001) and in the
septal interstitium (0.027 ± 0.014 vs. 0.067 ± 0.039, p = 0.026). The lung tissue of IM-TOL, when compared to IM,
showed decreased immunostaining of types I, III and V collagen, reduced mRNA expression of types I (0.10 ± 0.07
vs. 1.0 ± 0.528, p = 0.002) and V (1.12 ± 0.42 vs. 4.74 ± 2.25, p = 0.009) collagen, in addition to decreased TGF-beta
expression (p < 0.0001).
Conclusions: Collagen V-induced nasal tolerance in the experimental model of SSc regulated the pulmonary
remodeling process, inhibiting collagen deposition and collagen I and V mRNA synthesis. Additionally, it decreased
TGF-beta expression, suggesting a promising therapeutic option for scleroderma treatment.
Background
Progressive Systemic Sclerosis (SSc) is an autoimmune
disease of unknown pathogenesis, characterized by the
increased extracellular matrix (ECM) synthesis, vascular
remodeling and autoantibody emergence, which results
in scarring in multiple organs. The lung is usually
involved, and is the main cause of mortality in this dis-
ease [1]. Interstitial lung fibrosis, of variable intensity,
affects approximately 90% of patients, and the frequency
of pulmonary hypertension varies from 5% to 35% [1]. A
diagnosis of SSc has important prognostic implications
owing to the clinical course marked by inexorable dete-
rioration. Currently, no medical therapies have proved
to prolong life expectancy. Thus, there is great interest
in understanding lung involvement in SSc and the
effects of treatment to avoid irreversible scarring and
decreased survival. Although the exact mechanism of
treatment effects remains unknown, the influence of
immune inflammatory cells and their mediators is
diminished in animal models [2,3], thus affecting * Correspondence: matrix@lim17.fm.usp.br
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ECM remodeling.
Because ECM remodeling is thought to promote pul-
monary restoration, a group of collagens have been tar-
geted as potentially useful indicators of ECM
remodeling [4,5]. Specifically, collagen V is a promising
indicator [6]. Collagen V is a highly conserved molecule
among different animal species [4,5] and is normally
found in lung ECM, composing the heterotypic fibrils
with types I and III collagen. Collagen V is a minor col-
lagen fraction not normally exposed in the tissues
[7-10], retaining the amino- and carboxy-terminals,
making it quite immunogenic.
Previously, we discovered an experimental model of
S S cb yi m m u n i z i n gh e a l t h yN ew Zealand rabbits with
h u m a nc o l l a g e nVe m u l s i f i e dw i t hF r e u n d ’s adjuvant.
This resulted in intense inflammation of the lung and
progressive ECM remodeling of the septal and broncho-
vascular axis [11]. The examination of other organs
usually affected in SSc, such as skin, esophagus, kidney,
heart and synovial membrane, showed identical and
intense ECM remodeling [12-14]. In addition, several
immunological alterations were observed, such as the
presence of types I, III and IV anti-collagen antibodies,
circulating immune complexes, and the emergence of
antinuclear antibodies (ANA) and anti-Scl-70 antibodies
[15]. Based on Sakkas’s works [16,17] suggesting that
SSc pathogenesis is related to the activation of T cells
by still unidentified antigens, we postulated that collagen
V usually found hidden between collagen I and III in
heterotypic fibers, but exposed in our experimental
model, could be one of the antigens responsible for trig-
gering the T-dependent response (Th2). The activated
Th2 cells and the IL-4 and IL-17 cytokines generated by
their activation would explain the SSc triad: increased
ECM synthesis, vascular remodeling and autoantibody
production [17]. These alterations associated with the
immunogenic role of collagen V make our experimental
model important to test tolerance induction in the treat-
ment of SSc. Considering that we have already demon-
strated the efficacy of nasal tolerance with collagen V in
skin remodeling of animals with SSc [18], in the present
study we evaluated the amount of collagen deposition,
mRNA collagen synthesis and TGF-beta expression in
pulmonary septal and bronchovascular interstitium of
rabbits after collagen V-induced nasal tolerance in
experimental SSc. It was hypothesized that collagen V-
induced nasal tolerance decreases the density of pul-
monary perivascular and septal collagenous fibers.
Methods
Collagen V Immunization
Experimental SSc was induced in healthy New Zealand
female rabbits (N = 12) with a mean weight of 2.50 Kg
and 2 months of age. The complete immunization pro-
tocol includes 4 inoculations. The first is a subcutaneous
(sc) injection with 1 mg of Col V isolated from human
placenta [11-15], diluted in 1 ml of 10 mM acetic acid
and added to an equal amount of complete Freund’s
adjuvant (Sigma Chemical Co.; St. Louis, Missouri,
USA). The second inoculation occurs after 30 days and
the animals received an identical subcutaneous injection.
Fifteen days after the second subcutaneous injection, the
rabbits received one reinforcement dose of 1 mg of Col
V plus 1 ml incomplete Freund’s adjuvant intramuscu-
larly (third inoculation). Finally, a second identical rein-
forcement (fourth inoculation) is administrated after
another 15 days [11-15]. The control group (N = 6) was
inoculated with Freund’s adjuvant diluted in 10 mM of
acetic acid, following the same protocol of the immu-
nized animals.
Collagen V-Induced Nasal Tolerance
Nasal tolerance was induced in a group of six collagen
V-immunized animals, through the nasal administration
of daily doses of 25 μg of collagen V diluted in 25 μlo f
10 mM acetic acid (IM-TOL). The nasal tolerance
induction was initiated 150 days after the first immuni-
zation, and conducted for 60 days. Another group of six
immunized animals (IM) was not tolerated. The control
group (n = 6), inoculated with Freund’sa d j u v a n t( CT-
FA) was tolerated by nasal route with collagen V,
initiated 150 days after immunization. All animals were
sacrificed at 210 days.
The animal procedures were approved by the Ethics
Committee in Research, CAPPesq of the Clinical Board
of the School of Medicine, University of São Paulo, as
stated in Protocol of Research number 268/05.
Collagenous Fibers Histomorphometric Analysis
To characterize the collagenous fibers in peribroncho-
vascular and septal pulmonary interstitium, Masson’s
trichrome was used to stain the collagen-containing
fibers in blue. Also, the Picrosirius staining method [19]
observed under polarized light was used to intensify the
normal birefringence of collagenous fibers and to deter-
mine the location of collagen-containing fibers. The
number of collagen fibers in lungs was determined by
an image analysis system in an optical microscope
equipped with a light polarizer coupled to an image ana-
lyzer. The system consisted of a Q-Color 5 camera,
coupled to an Olympus microscope, from which the
images could be visualized on the monitor. The images
were processed through a digital system installed in a
computer (Pentium 4, 300 Mhz) using the Image-Pro-
Plus, version 6.0 software. The enhancement of collagen
birefringence promoted by the Picrosirius polarization
method is specific for collagenous structures composed
of aggregates of orientated molecules. The threshold for
collagenous fibers was established for each slide after
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were easily identified as birefringent (collagen) bands.
The area occupied by the fibers was determined by digi-
tal densitometric recognition, by adjusting the threshold
level of measurement to all the fibers of the collagenous
system. The collagen content was measured in the peri-
bronchovascular and septal interstitium and expressed
as a relationship between the quantities of collagen
fibers divided by the total area of interstitium studied.
The area of septal and bronchovascular interstitium in
each specimen was carefully measured in the image ana-
lysis system using a cursor that allowed the free deter-
mination of the area between the basement membrane
(septal interstitium) and the periadventitial layer
(bronchovascular interstitium). The results express the
amount of fibers of the collagenous systems (in area)
per total area of interstitium, expressed as a fraction.
Collagen I, III and V Immunofluorescence
Transversal sections of rabbit lungs prepared in slides
that were previously treated with 3 - aminopropil-
triethoxy Silano (Sigma Chemical Co., St. Louis, MO,
USA) were immersed in hot (60°C) xylol for 20 min and
then submitted to three cold xylol washings and
hydrated with successive washings in ethanol, at
decreasing concentrations (100%-75%), distilled water
and phosphate buffer (PBS). For the exposition and
recovery of the antigenic sites, the material was digested
with pig pepsin (10,000 U/ml) (Sigma Chemical Co.)
dissolved in 1 mM acetic acid, for 30 min at 37°C. The
treated sections were washed three times, for 10 min
each, with PBS and incubated with type I or V anti-col-
lagen mouse polyclonal antibody, diluted at 1:50 in PBS,
and type III anti-collagen monoclonal antibody (Calbio-
chem), with a 1:50 dilution during the night. After this
incubation, the cuts were washed in PBS with 0.05%
Tween20 and incubated for 90 min with anti-IgG mouse
secondary antibody conjugated with fluorescein (Sigma
Chemical Co.) diluted at 1:50 in a PBS solution, contain-
ing 0.006% Evans blue and mounted with a buffered gly-
cerol solution. The reaction was visualized in a Nikon
fluorescence microscope.
Collagen I, III and V Real-time PCR (RT-PCR)
Selected specimens from peripheral areas of the lower
pulmonary lobe were pulverized (Bio-Pulverizer™ BioS-
pec Products Inc., Oklahoma, USA) under liquid
nitrogen and total RNA was isolated using Trizol
reagent (Invitrogen Corporation, Carlsbad, CA, USA),
according to the manufacturer’s protocol. RNA quality
and integrity were verified by the absorbance 260
nm:280 nm ratio (A260/280), which varied between 1.78
and 2.0, and through observation of 28S/18S rRNA on
agarose gel (1%) electrophoresis, in denaturing condi-
tions and visualization with ethidium bromide (ratio >
1.0).
Total RNA (4 μg) was reverse-transcribed using a hex-
amers primer (0.5 μg/μl) (GE Healthcare Life Sciences,
Little Chalfont, St. Giles, UK) and Superscript III (Invi-
trogen Corp., Carlsbad, CA, USA). Real-time RT-PCR
was conducted using SYBR-green I (Sigma Chemical
Co.) in a Rotor-gene system (Corbett Research, Mor-
tlake, Australia). Amplification reactions were conducted
using 125 ng of cDNA, 1.25 U Platinum Taq Polymerase
(Invitrogen), polymerase buffer (Invitrogen), 2.0 mM
MgCl2, 200 μM each dNTP, 0.3 μMe a c hp r i m e r ,5 %
DMSO and 0.1 μL SYBR® Green. Amplification condi-
tions consisted of denaturation at 95°C for 15 s followed
by 40 cycles of annealing at 56°C for 60 s, and extension
at 72°C for 60 s.
Primer sets were designed based on the coding region
closer to the 3’ end of the gene using Primer3 (Table 1).
Sequences, present in different exons preferentially sepa-
rated by long introns, were selected according to
sequences deposited at http://www.ncbi.nlm.nih.gov/
nucleotide. BLAST analysis http://www.ncbi.nlm.nih.
gov/blast was conducted to avoid non-specific product
formation. To minimize self- and cross-dimer hairpin
formation, homodimer melting temperatures were veri-
fied using the program OligoTech version 1.00, Copy-
right 1995 (Oligos Etc. Inc. & Oligo Therapeutics Inc.).
All samples were tested in duplicate and analyzed by
the software Rotor-Gene 6 System (Corbett Research).
Results displaying variation in CT - the cycle number at
which logarithmic PCR plots cross a calculated thresh-
old line - of less than 1.5 were used to calculate average
values.
Data were expressed as CT values. Relative expression
of genes of interest was normalized to that of GAPDH,
and gene expression in each sample was then compared
with expression in pool cells. The comparative CT
method (ΔΔCT) was used for the quantification of gene
Table 1 Sequence and description of the genes selected for the study
Gene Genbank Accession
Number
Primer sense (5’-3’) Primer antisense (5’-3’) Product size (pb)
COL I AY633663 CTTGGGGTTCTTGCTGATGT GGACCTCAAGATGTGCCACT 178
COL III S83371 ATGTGTTTGGTGGAACAGCA TGGCCCTGTTTGCTTTTTAT 204
COL V AF451329 GTCCCCCTCAAACACTTCCT TCTCAGCGTCCACAAGAAAA 154
GAPDH AB231852 GTGAGTTTCCCGTTCAGCTC AGGTCATCCACGACCACTTC 202
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-
ΔΔCT [20].
TGF-beta Expression
To evaluate TGF-beta in pulmonary septal and peri-
bronchovascular interstitium, 4-μm paraffin sections
were immunohistochemically stained with goat polyclo-
nal TGF-beta (Santa Cruz Biotechnology Inc.; dilution
1:100) according to the labeled Streptavidin-Biotin Com-
plex method used previously in others’ works [21]. To
quantify stained cells, a point-counting stereologic
method [19] was employed using a reticulum formed by
100 points and 50 lines, each measuring 25 μmi n
length, adapted to a conventional microscope. At 400×
magnification, the vessels and septal interstitium in each
field were calculated according to the number of points
hitting connective tissue, as a proportion of the total
grid area. Then, we counted the number of positive cells
within the pulmonary interstitium area. The TGF-beta
expression was determined as the number of positive
cells in each field divided by the interstitium area. The
final results were then transformed to cells/mm
2 by
adjusting the units.
Statistical analysis
Differences between the groups were determined by the
Shapiro-Wilks test to determine normality and Levene’s
one-way test for the homogeneity of variance. Indepen-
dent-samples t test for two comparison and ANOVA
with Bonferroni test for multiple comparison were per-
formed when appropriate. All statistical procedures were
performed with SPSS version 10.0 statistical software for
Windows® (Norusis M.J., SPSS, Inc., Chicago, IL). The
level of significance was determined to be p < 0.05.
Results
Figure 1 shows, respectively, lung samples obtained from
immunized and tolerated animals stained by Masson’s
trichrome and Picrosirius under polarized light. Lungs
of rabbits examined 210 days after the first inoculation
(Figure 1A, B) presented prominent thickness of the
septal and bronchovascular interstitium and increased
reddish-yellow birefringence, indicating the presence of
thick fibers, characteristic of the fibrotic process (Figure
1 E ,F ) .I nc o n t r a s t ,l u n g sf r o mt o l e r a t e da n i m a l ss h o w
preservation of septal and peribronchovascular intersti-
tium thickness (Figure 1C, D) coincident with the weak
yellow birefringence of the fibers (Figure 1G, H).
The density of the collagen fibers is decreased around
the vessels (0.371 ± 0.118 vs. 0.874 ± 0.282; p < 0.001),
bronchioles (0.294 ± 0.139 vs. 0.646 ± 0.172; p < 0.001)
and in the septal interstitium (0.027 ± 0.014 vs. 0.067 ±
0.039, p = 0.026) in tolerated animals when compared
to the immunized ones (Figure 2A, B and 2C).
The immunolabeling for collagen I in the lung tissue
of immunized animals showed a dense and
heterogeneous pattern of fluorescence, more intense
around the peribronchovascular interstitium than along
the septal interstitium (Figure 3A). The immunoexpres-
sion of collagen III was equally intense along the
bronchovascular interstitium of immunized animals,
mainly in the adventitia of the pulmonary artery (Figure
3B). As for the expression of the collagen V, the immu-
nized animals showed intense labeling, seen as thick
fibers along the bronchovascular interstitium and the
septal interstitium, thus differing from its normal fibril-
lar pattern of thin fibers (Figure 3C). In the group toler-
ated with collagen V, the lung tissue presented a
homogeneous labeling pattern, characterized by the
decreased fluorescence intensity for collagen I in the
bronchovascular interstitium and the septal interstitium
(Figure 3D), as well as decreased expression of collagen
III, with a thin fiber pattern in all analyzed regions (Fig-
ure 3E). The expression of collagen V in the group of
tolerated animals shows a reversion to the thin fibrillar
pattern, characteristic of the expression of this type of
collagen in the bronchi and vessels of these animals
(Figure 3F).
The expression of mRNA in lung tissue is significantly
decreased in the group of animals tolerated with col-
lagen V (IM-TOL), when compared to the animals that
were only immunized (IM), for types I (0.10 ± 0.07 vs.
1.0 ± 0.528, p = 0.002) and V (1.12 ± 0.42 vs. 4.74 ±
2.25, p = 0.009) collagen. There is no significant differ-
ence in the expression of collagen I between tolerated
(IM-TOL) and control (CT-FA) groups (p = 0.357). A
marginal significance was found for lower mRNA col-
lagen V expression in tolerated (IM-TOL) group com-
pared to control (CT-FA) (p = 0.073). Collagen III
mRNA expression showed no difference between toler-
ated (IM-TOL) and immunized (IM) animals (3.2 ± 2.17
vs. 3.07 ± 1.03, p = 0.628) (Figure 3G, H and 3I).
Figure 4A shows the slight expression of TGF-beta in
the endothelium and epithelium of control lungs con-
trasting with the significant cytokine labeling in the
endothelium and epithelium in immunized animals (Fig-
ure 4B, C; Table 2). In tolerated animals, one can
observe a significant attenuation of the TGF-beta cyto-
kine expression in the endothelium and epithelium (Fig-
ure 4D, Table 2).
Discussion
Currently, no medical therapies can alter the disease
course of SSc, especially in the presence of pulmonary
complications. SSc is not cured with immunosuppressive
therapies, and may have its clinical course marked by
serious adverse effects, such as medullary depression,
systemic infections, hepatopathy, or nephropathy. Drugs
employed in the treatment of pulmonary hypertension,
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Page 4 of 10Figure 1 Transversal sections of lungs of immunized rabbits, and lungs after nasal tolerance induction with collagen V, stained by
Masson trichromic (A-D) and Picrosirius (E-H). In the immunized animals, thickening of the extracellular matrix is observed, with radial and
periaxial distribution (A, B, E, F). After the induction of nasal tolerance with collagen V, there was a decrease in collagen deposition (G, H). TB =
terminal bronchiole; V = vessel; Groups: IM = immunized; IM-TOL = immunized and tolerated; Magnification: 200×.
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restricted use, and, thus, are not routinely prescribed.
In the present study, we demonstrated that the treat-
ment of pulmonary complications in animals with SSc
through the induction of nasal tolerance with collagen
V, showed similar results to those previously obtained in
rabbit skin, when submitted to this procedure [18]. We
didn’t find a progression of the disease process which
was characterized by a decrease in interstitial fibrosis
and vascular sclerosis, as well as lower expression of col-
lagens I and V and pro-fibrotic cytokines. Tolerance
induction inhibits the systemic immunological response
through the administration of specific antigens, which
are important in the pathogenesis of immunological dis-
eases, via the mucosa (nasal or oral), leading to the pre-
vention and/or treatment of autoimmune and allergic
diseases or preventing transplant rejection [22].
The mechanisms of tolerance induction depend on the
dose used. High doses induce T-cell deletion or anergy,
and low doses promote regulatory T-cell activation
(regT), such as TH3, which produces TGF-beta and Tr1
cells that generate cytokines IL-10 and IL-4; both of
these cytokines have immunosuppressive activity
[23-27]. Thus, for all these reasons, we should not to be
surprised to learn that collagen V nasal tolerance didn’t
allow the progression of the fibrotic process and the
pulmonary and vascular remodeling, and our results
now confirm the therapeutic importance of collagen V
role in an experimental model of SSc.
We also confirmed the improvement in the histologi-
cal parameters by molecular analysis. In fact, animals
submitted to nasal tolerance induction with collagen V
showed a decrease in the mRNA expression for col-
lagens I and V. We believe that the collagen III expres-
sion showed no difference between only immunized and
tolerated animals during the fibrosis period, since this
collagen is normally expressed in more initial fibrosis.
The collagen synthesis normalization in the experimen-
tal animals after the tolerance induction with collagen
V, discloses, for the first time, the possibility of avoid
fibrosis progression in an SSc experimental model. The
present study also shows that the fibrosis observed in
the experimental model of SSc may be structurally dif-
ferent from the physiological fibrosis of tissue repair. In
the physiological healing processes, which are consid-
ered irreversible, the proportions of collagens I, III and
V do not change. This differs from the remodeling pro-
cess in SSc, where there is a disproportionate expression
of collagen V. Further studies in randomized and pro-
spective trials will be necessary to determine whether
this defective tissue architecture exhibited by animals
with SSc is the consequence of an aberrant fibroblast or
if there is an atypical molecular arrangement of the col-
lagens that constitute the heterotypic fibers (collagens I,
Figure 2 Charts A, B and C show the content of collagen
fibers among the groups. A significant decrease in collagen fiber
density in the vascular wall (p < 0.001) (A), in the bronchioles (p <
0.001) (B) and the pulmonary interstitium (p = 0.026) (C) was
observed in tolerated animals, when compared to immunized ones.
No difference was observed in the content of collagen between
control and tolerated animals. Groups: CT-FA = Freund’s adjuvant
control; IM = immunized; IM-TOL = immunized and tolerated.
Statistical analysis was employed by ANOVA with Bonferroni test.
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lagen V.
This report provides previously undescribed morpho-
logical insight into the pathogenesis of SSc and expands
the scope of diseases associated with autoantigens, such
as collagen V. We predict that collagen V is one of the
antigens involved in the activation of Th2 subtype lym-
phocytes, which initiates the synthesis of pro-fibrotic
cytokines and stimulates the immunological system to
produce autoantibodies [16,17]. The nasal tolerance
mechanism with collagen V inhibits this anomalous
immunological response, leading to the normalization of
the inflammatory process and thus avoiding the
anomalous matrix remodeling. We also demonstrated
the excessive production of TGF-beta, the main pro-
fibrotic cytokine, and its normalization after the nasal
tolerance induction with collagen V. In an autoimmu-
nity model such as SSc presenting a severe fibrotic
involvement of organs, the decrease in TGF-beta is
interesting, since this cytokine is fibrogenic [28].
The above considerations have support in the litera-
ture. Recently, several author sc o n f i r m e dt h a tc o l l a g e n
V is, in fact, an autoantigen, also capable of inducing
lung transplant rejection in a murine experimental
model [7,8,29-33]. Yoshida et al [32] also showed the
importance of specific T cells sensitized for collagen V
Figure 3 Panels A to F show the lungs of rabbits immunolabeled with types I, III and V collagen by immunofluorescence. A decrease
in the expression of collagens I (D), III (E) and V (F) in the peribronchovascular interstitium and in the septal interstitium of tolerated animals was
observed when compared to immunized animals (A, B and C, respectively). Panels G, H and I show the differential gene expression of the mRNA
for collagens I, III and V, respectively, in lung tissue of control and immunized animals and after the induction of nasal tolerance with collagen V.
The box plot shows the distribution of all values between the bars (quartiles 25, 50 and 75 within the box), except extreme values (°1.5- to 3.0-
fold the dimension of the box of the 75th percentile; *values that are more than 3-fold the dimension of the box of the 75th percentile). The
Bonferroni test was used, and we considered the gene to be differentially expressed where p ≤ 0.05. TB = terminal bronchiole; V = Vessel;
Magnification: A-F, 400×. Groups: CT-FA = Freund’s adjuvant control; IM = immunized; IM-TOL = immunized.*Statistical significance.
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of lung transplant. They demonstrated that the oral tol-
erance with collagen V was capable of inhibiting the
acute rejection of the lung graft, preventing the develop-
ment of bronchiolitis obliterans, a main causal factor of
death in lung transplants in mouse experimental models
as well as in transplanted humans [32-34]. In addition,
Mizobuchi et al [35] identified regulatory T cells (CD4
+CD45RC
higth) that mediated tolerance for collagen V in
lung transplants in an experimental rat model.
To date, the therapeutic approach by inducing
immune tolerance obtained in our model cannot be
directly transferred into the human situation without
any precautions. However, few studies published in the
literature show that patients that have been tolerated
with bovine collagen I by the oral route exhibit a
Figure 4 Rabbit lungs immunolabeled with TGF-beta by immunoperoxidase. A decrease in the expression of TGF-beta in the vascular
endothelium cells and bronchial epithelium of tolerated animals (D) was observed when compared to immunized ones (B, C). There was no
significant difference in immunolabeling for TGF-beta between tolerated (D) and control animals (A). TB = terminal bronchiole; V = vessel;
Magnification: 400×. Groups: CT-FA = Freund’s adjuvant control; IM = immunized; IM-TOL = immunized and tolerated.
Table 2 The TGF-beta expression in vessels and septal interstitium from lungs of control, immunized and type V-
induced nasal tolerance rabbits groups
CONTROL IMMUNIZED TOLERATED P
VESSEL
Endothelium cells 6.7 ± 3.85 43.5 ± 5.7 10.77 ± 4.3 *p < 0.0001
Smooth muscle cells 11.04 ± 1.0 53.68 ± 4.06 9.93 ± 3.77 *p < 0.0001
SEPTAL INTERSTITIUM
Epithelial cells 5.04 ± 2.46 13.65 ± 1.39 6.03 ± 1.47 *p < 0.0001
Interstitial Fibroblasts 8.55 ± 1.96 20.13 ± 1.60 11.55 ± 1.88 *p < 0.0001
* p = immunized vs. tolerated; ANOVA with Bonferroni test was employed to statistical analysis.
The results are reported as cells/mm
2.
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vitro collagen I and a considerable clinical improvement
[36]. More recently, Postlethwaite et al [37] demon-
strated that oral tolerance induction with type I bovine
collagen, administrated for a period of 15 months, sig-
nificantly decreased the skin thickening in patients with
more advanced manifestations of SSc. More studies are
necessary to suggest that tolerance with collagen V
could be an alternative approach for the treatment of
human SSc such as collagen I.
Conclusions
We conclude that collagen V-induced nasal tolerance is
an effective therapeutic procedure in reducing inflam-
mation and remodeling that occurred at the cost of col-
lagen deposition in the lungs of animals with SSc. The
fact that the progression of the fibrotic disease can be
avoided in the SSc experimental model predicts remark-
able advances in the treatment of this severe disease.
Abbreviations
SSc: Systemic sclerosis; ECM: Extracellular matrix; mRNA: messenger; TGF-
beta: Transforming growth factor; IM: Immunized; IM-TOL: Immunized and
Tolerated; CT-FA: Freund’s adjuvant control; PCR: Polymerase Chain
Reaction; RT-PCR: Reverse Transcriptase Polymerase Chain Reaction; ANA:
Antinuclear antibodies; IL: Interleukin; PBS: Phosphate buffered saline; dNTP:
Nucleotides; DMSO: Dimethyl sulfoxide; BLAST: Basic Local Alignment
Search Tool; CT: Cycle threshold; GAPDH: Glyceraldehyde-3-phosphate
dehydrogenase; ANOVA: Analysis of variance between groups; SPSS:
Statistical Package for the Social Sciences.
Acknowledgements
This study was supported by the following agencies: Foundation for the
Support of Research of the State of São Paulo (FAPESP) and Laboratories for
Medical Research (LIMs), University Hospital, School of Medicine, University
of São Paulo and Federico Foundation. We thank Celina Helena Araújo for
preparing the lung slides and Angela Batista Gomes dos Santos and Maria
Cristina Rodrigues Medeiros for immunohistologic procedures.
Author details
1Rheumatology Division of the School of Medicine of the University of São
Paulo (FMUSP), São Paulo, SP, Brazil.
2Department of Radiology, Discipline of
Oncology of the School of Medicine of the University of São Paulo (FMUSP),
São Paulo, SP, Brazil.
3Department of Pathology of the School of Medicine of
the University of São Paulo (FMUSP), São Paulo, SP, Brazil.
Authors’ contributions
APPV carried out the induction of the experimental scleroderma model and
nasal tolerance and the immunofluorescence experiments, and drafted the
manuscript; WRT contributed to conception and design of the original study
and analysis and interpretation of histological, immunohistochemical and
molecular data; DMA and ERP contributed to the acquisition of histologic
and morphometric data and performed the statistical analysis; RK, CCO and
MHK contributed to the acquisition of molecular data and performed the
statistical analysis; VLC and NHY were involved in drafting the manuscript
and revising it for important intellectual content. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 September 2009
Accepted: 4 January 2010 Published: 4 January 2010
References
1. Dorfmüller P, Humbert M, Perros F, Sanchez O, Simonneau G, Müller KM,
Capron F: Fibrous remodeling of the pulmonary venous system in
pulmonary arterial hypertension associated with connective tissue
diseases. Hum Pathol 2007, 38(6):893-902.
2. Lakos G, Takagawa S, Varga J: Animal models of scleroderma. Methods Mol
Med 2004, 102:377-93.
3. Nguyen VA, Sgonc R, Dietrich H, Wick G: Endothelial injury in internal
organs of University of California at Davis line 200 (UCD 200) chickens,
an animal model for systemic sclerosis (Scleroderma). J Autoimmun 2000,
14(2):143-149.
4. Niyibizi C, Fietzek , Rest M: Human placenta Collagen Vs. Evidence for
existence of a a1(V), a2(V), a3(V). Col Mol 1984, 259:14170-4.
5. Imamura Y, Scott IC, Greenspan DS: The pro-alpha 3(V) collagen chain.
Complete primary structure, expression domains in adult and
developing tissues, and comparison to the structures and expression
domains of the other types V and XI procollagen chains. J Biol Chem
2000, 275(12):8749-59.
6. Madri JA, Furthmayr H: Collagen Polymorphism in the Lung-An
Immunochemical Study of Pulmonary Fibrosis. Human Pathology 1980,
11(4):353-66.
7. Wilkes DS: Autoimmune responses to grafted lungs: immune responses
to a native collagen-Collagen V. Graft 2003, 6(1):42-9.
8. Wilkes DS: The role of autoimmunity in the pathogenesis of lung
allograft rejection. Arch Immunol Ther Exp (Warsz) 2003, 51(4):227-230.
9. Unsöld C, Pappano WN, Imamura Y, Steiglitz BM, Greenspan DS:
Biosynthetic processing of the pro-1 (V)2 pro-2(V) collagen heterotrimer
by bone morphogenetic protein-1 and furin-like proprotein convertases.
J Biol Chem 2002, 277(7):5596-602.
10. Sato K, Tanahashi-Siina T, Jun F, Watanabe-Kawamura A, Ichinomiya M,
Minegishi Y, Tsukamasa Y, Nakamura Y, Kawabata M, Ohtsuki K: Simple and
rapid chromatographic purification of Collagen V from a pepsin digest
of porcine instestinal connective tissue, an unmanageable starting
material for convenctional column chromatography. J Chromatogr 2003,
790:277-83.
11. Teodoro WR, Velosa AP, Witzel SS, Garippo AL, Farhat C, Parra ER,
Sonohara S, Capelozzi VL, Yoshinari NH: Architectural remodelling in lungs
of rabbits induced by Collagen V immunization: a preliminary
morphologic model to study diffuse connective tissue diseases. Pathol
Res Pract 2004, 200(10):681-691.
12. Bezerra MC, Teodoro WR, de Oliveira CC, Velosa AP, Ogido LT, Gauditano G,
Parra ER, Capelozzi VL, Yoshinari NH: Scleroderma-like remodeling induced
by Collagen V. Arch Dermatol Res 2006, 298(2):51-57.
13. Yoshinari NH, Teodoro WR, Ogido LTI, Velosa APP, Prizon CP, Miron B,
Bissoli JCC, Cuentas ERP, Capelozzi VL: Modelo experimental de doenças
difusas do tecido conjuntivo (DDTC) induzido por colágeno do tipo V.
Rev Bras Reumatol 2002, 42:295-305.
14. Teodoro WR, Miron BG, Tsuzuki L, Ogido I, Velosa AP, Abatepaulo F,
Capelozzi VL, Yoshinari NH: Synovial remodeling process induced by
Collagen V immunization in rabbits. Pathol Res Pract 2003, 199(9):605-612.
15. Callado MR, Viana VS, Vendramini MB, Leon EP, Bueno C, Velosa AP,
Teodoro WR, Yoshinari NH: Autoantibody profile in the experimental
model of scleroderma induced by type V human collagen. Immunology
2007, 122(1):38-46.
16. Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez S, A Platsoucas CD: Oligoclonal T
Cell Expansion in the Skin of Patients with Systemic Sclerosis. J Immunol
2002, 168:3649-3659.
17. Sakkas LI, Platsoucas CD: Is systemic sclerosis an antigen-driven T cell
disease?. Arthritis Rheum 2004, 50(6):1721-1733.
18. Velosa AP, Teodoro WR, de Oliveira CC, dos Santos Filho A, Moutinho RF,
Santos AG, Vendramini MB, Bueno C, Parra ER, Capelozzi VL, Yoshinari NH:
Collagen V nasal tolerance in experimental model of systemic sclerosis.
Arch Dermatol Res 2007, 299(4):177-189.
19. Gundersen HJ, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen N,
Møller A, Nielsen K, Nyengaard JR, Pakkenberg B: The new stereological
tools: disector, fractionator, nucleator and point sampled intercepts and
their use in pathological research and diagnosis. APMIS 1988, 96(10):857-
881.
20. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001, 25(4):402-408.
Velosa et al. Respiratory Research 2010, 11:1
http://respiratory-research.com/content/11/1/1
Page 9 of 1021. Parra ER, Kairalla RA, Ribeiro de Carvalho CR, Eher E, Capelozzi VL:
Inflammatory cell phenotyping of the pulmonary interstitium in
idiopathic interstitial pneumonia. Respiration 2007, 74:159-69.
22. Mestecky J, Moldoveanu Z, Elson CO: Immune response versus mucosal
tolerance to mucosally administered antigens. Vaccine 2005, 23(15):1800-
1803.
23. Faria AMC, Weiner HL: Oral tolerance: mechanisms and therapeutic
application. Adv Immunol 1999, 73:153-265.
24. Weiner HL: Oral tolerance: immune mechanisms and the generation of
Th3-type TGF-b-secreting regulatory cells. Microbes Infect 2001, 3(11):947-
954.
25. Faria AMC, Weiner HL: Oral tolerance. Immunol Rev 2005, 206:232-259.
26. Faria AM, Weiner HL: Oral tolerance: Therapeutic implications for
autoimmune diseases. Clin Dev Immunol 2006, 13(2):143-157.
27. Jonuleit H, Schmitt E: The Regulatory T cell family: Distinct subsets and
their interrelations. J Immunol 2003, 17(12):6323-6327.
28. Ihn H: Autocrine TGF-b signaling in the pathogenesis of systemic
sclerosis. J Dermatol Sci 2008, 49(2):103-113.
29. Mares DC, Heidler KM, Smith GN, Cummings OW, Harris ER, Foreman BH,
Cummings OW, Harris ER, Foresman B, Wilkes DS: Collagen V modulates
alloantigen-induced pathology and immunology in the lung. Am J Respir
Cell Mol Biol 2000, 23:62-70.
30. Haque MA, Myzobuchi T, Yasufuku K, Fujisawa T, Brutkiewicz RR, Zheng Y,
Woods K, Smith GN, Cummings OW, Heidler KM, Blum JS, Wilkes DS:
Evidence for immune responses to a self antigen in lung
transplantation: role of Collagen V-specific T cells in the pathogenesis of
lung allograft rejection. J Immunol 2002, 69:1542-1549.
31. Sumpter TL, Wilkes DS: Role of autoimmunity in organ allograft rejection:
a focus on immunity to Collagen V in the pathogenesis of lung
transplant rejection. Am J Physiol Lung Cell Mol Physiol 2004, 286(6):L1129-
L1139.
32. Yoshida S, Haque A, Mizobuchi T, Iwata T, Chiyo M, Webb TJ, Baldridge LA,
Heidler KM, Cummings OW, Fujisawa T, Blum JS, Brand DD, Wilkes DS: Anti-
Collagen V lymphocytes that express IL-17 and IL-23 induce rejection
pathology in fresh and well-healed lung transplants. Am J Transplant
2006, 6(4):724-735.
33. Yasufuku K, Heidler KM, O’Donell PW, Smith GN Jr, Cummings OW,
Foresman BH, Fujisawa T, Wilkes DS: Oral tolerance induction by Collagen
V Downregulates lung allograft. Am J Respir Cell Mol Biol 2001, 25(1):26-34.
34. Garippo AL, Parra ER, Teodoro WR, Veloza AP, Yoshinari NH, Capelozzi VL:
Immune cell infiltration and broncovascular remodeling after nitric acid
nasal instillation in a mouse bronchiolitis obliterans model. Lung 2006,
184(4):229-38.
35. Mizobuchi T, Yasufuku K, Zheng Y, Haque MA, Heidler KM, Woods K,
Smith GN Jr, Cummings OW, Fujisawa T, Blum JS, Wilkes DS: Differential
expression of Smad7 transcripts identifies the CD4+CD45RChigh
regulatory T cells that mediate Collagen V-induced tolerance to lung
allografts. J Immunol 2003, 171(3):1140-1147.
36. Mckown KM, Carbone LD, Bustillo J, Seyer JM, Kang AH, Postlethwaite AE:
Induction of immune tolerance to human type I collagen in patients
with systemic sclerosis by oral administration of bovine type I collagen.
Arthitis Rheum 2000, 43(5):1054-1061.
37. Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH,
Korn J, Mayes M, Merkel PA, Molitor JA, Moreland L, Rothfield N, Simms RW,
Smith EA, Spiera R, Steen V, Warrington K, White B, Wigley F, Furst DE: A
multicenter, randomized, double-blind, placebo-controlled trial of oral
type I collagen treatment in patients with diffuse cutaneous systemic
sclerosis: I. oral type I collagen does not improve skin in all patients, but
may improve skin in late-phase disease. Arthritis Rheum 2008, 58(6):1810-
1822.
doi:10.1186/1465-9921-11-1
Cite this article as: Velosa et al.: Collagen V-induced nasal tolerance
downregulates pulmonary collagen mRNA gene and TGF-beta
expression in experimental systemic sclerosis. Respiratory Research 2010
11:1.
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Velosa et al. Respiratory Research 2010, 11:1
http://respiratory-research.com/content/11/1/1
Page 10 of 10